The Department of Hematology of the First Affiliated Hospital Zhejiang University School of Medicine is one of the best and largest of its kind in China integrating teaching, health care and scientific research on the basis of the largest number of beds, a balanced development of sub-specialties and strong comprehensive strength. In the early 1950s, the Department was founded by Professor Yu Zhifei, a famous hematologist. For decades, we have attached great importance to close integration of basic research and clinical research. Our team focuses on the introduction of international advanced technology and the combination of clinical diagnosis and treatment technology. Therefore, it has ranked 5th for six consecutive years in S&T Evaluation Metrics Ranking and the Best Reputation Ranking of Specialties in China. After decades of hard work, there are now 7 wards of hematology specialist wards, with a total of more than 360 beds. The Department is widely recognized for the diagnosis and treatment of hematological malignancies such as leukemia, malignant lymphoma, multiple myeloma, myelodysplastic syndrome and other hematological malignancies. It is home to several national and provincial key labs for basic and translational research, establishing a multi-level cooperation network and completing over 50 clinical researches on new drugs and treatment. 

Our department consists of 53 physicians, 26 technical staffs and 124 nurses, many of whom have gained national and international recognition for their clinical and/or research efforts. Our director and academic leader, Professor Jie Jin, is also the chief committee of Anti-leukemia Union (CSCO) and chairman of Chinese Female Physicians Association for Hematology. With the leading of Prof. Jin and the effort of every member, our department it has ranked Top 5 for six consecutive years in S&T Evaluation Metrics Ranking and the Best Reputation Ranking of Specialties in China. With respect to international cooperation, the Department has cooperated the City of Hope National Center, M.D. Anderson Medical Center and University of Cincinnati in the USA, Institut Curie in France, University of Western Australia and Keele

We have experience in treating all types of hematological diseases and conditions. Many patients come to our department when their condition is complex, or when common treatments have failed to work. We have professional teams of specialists and provincial key laboratory platform to support our diagnosis and treatment. The department provide the most advanced treatments for conditions including but not limited to:

Acute lymphocytic leukemia

Acute myelogenous leukemia

Amyloidosis

Anemia

Aplastic anemia

Autoimmune hemolytic anemias

Bleeding disorders

Castleman disease

Chronic lymphocytic leukemia

Chronic myelogenous leukemia

Chronic myelomonocytic leukemia

Essential thrombocythemia

Hairy cell leukemia

Hemoglobinopathies

Hemophilia

Hodgkin's lymphoma (Hodgkin's disease)

Hypereosinophilic syndrome

Immune thrombocytopenia (ITP)

Iron deficiency anemia

Lymphoma

Macroglobulinemia

Monoclonal gammopathy of undetermined significance (MGUS)

Multiple myeloma

Myelodysplastic syndromes

Myelofibrosis

Myeloproliferative disorders

Non-Hodgkin's lymphoma

Paroxysmal nocturnal hemoglobinuria

POEMS syndrome

Polycythemia vera

Thalassemia

Von Willebrand disease

We offer several treatments and procedures, including biological therapy for cancer, blood transfusion, bone marrow transplant, apheresis system, chemotherapy, experimental treatments, growth factor drugs, immunosuppressive drugs, immunotherapy, and targeted drug therapy.

Zhejiang Provincial Key Laboratory of Hematology Oncology Diagnosis and Treatment, led by principal investigator Jie Jin MD. PhD., is a lab designed for both basic science and translational studies. Research investigates many aspects of the biology and treatment of hematologic cancers and blood disorders. Laboratory research is focused on several frontier topics including: the metabolic disturbance of leukemia, epigenetic regulation, leukemia stem cells, and infections in malignant disorders. Clinical research centers on clinical trials of novel agents for the treatment of the broad range of blood disorders. We have initiated 161 clinical trials with 60 undergoing projects. Hundreds of articles have been published in biomedical journals over the past decades, including some high impact factor journals like Cell, the Lancet Oncology, Journal of Clinical Oncology, Blood etc. Our work is aimed at better understanding of hematological diseases and better treating the millions of patients now and in the future.

2004   Second prize of national science and technology progress award: The research for the unrelated allogeneic bone marrow transplantation.

2005   Second prize of national science and technology progress award: The collection, preservation and utilization of leukemia resources.

2007   Second prize of national science and technology progress award: The application of novel therapeutics for myelodysplastic syndrome.

2008   Second prize of national science and technology progress award: Regulating gene transfection of dendritic cells by telomerase and detecting the immunotherapy for leukemia.

2009   First prize of science and technology award of Zhejiang province: The basic and clinical researches on acute myeloid leukemia.

2010   First prize of Zhejiang provincial natural science award: A high complete remission rate after the first induction therapy by homoharringtonine combined with cytarabine and arubicin for treating primary myeloid leukemia.

2011   Second prize of national science and technology progress award: Detecting the biological characteristics, establishing and promoting the new chemotherapy strategies for acute myeloid leukemia.

2011   Second prize of science and technology award of Zhejiang province: The clinical and basic researches for non-Hodgkin's lymphoma.

2012   Second prize of science and technology award of Zhejiang province: The basic and clinical researches about reversing resistance and new therapies for multiple myeloma.

2012   Second prize of science and technology award of Zhejiang province: The role of dendritic cells in the treatment of leukemia.

2014   Second prize of science and technology award of Zhejiang province: The preclinical study of targeted therapies for acute leukemia.

2016   First prize of science and technology award of Zhejiang province: The Basic and clinical application researches of biomarkers and new therapies for acute myeloid leukemia

2018   Grand prize of Zhejiang medicine and health science and technology award: The basic and clinical researches on diagnosis and treatment for acute promyelocytic leukemia

2019   Second prize of science and technology award of Zhejiang Province: Detecting the new pathogenesis, establishing and applying the crucial diagnosis and treatment techniques for myelodysplastic syndrome.